1. Pink Sheet
  2. >>Market Access
  3. >>Pricing Debate

Senate Democrats Running Out Of Time On Drug Pricing Reform

 
• By Cathy Kelly

Is less ambitious drug pricing reform better than nothing? Senate Finance Committee Chair Wyden still pushing for a version of the most aggressive policy, direct government price negotiation.  

Finance Committee Chair Tilting At Windmills? • Source: Alamy

Senate Democrats hoping to reignite momentum behind drug pricing reform legislation continued to promote the direct Medicare price “negotiation” policy included in the now-stalled Build Back Better bill at a 16 March hearing in the Senate Finance Committee. But some Republicans suggested a more pragmatic approach might be to pursue policies that already have bipartisan support.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Pricing Debate

Raising Drug Prices In The EU Could Take Years, Even If Pharma Effort Succeeds

 
• By Cathy Kelly

Manufacturers are engaging the European Commission and individual countries to allocate more health care spending to innovative medicines and align prices more closely to those in the US.

PBMs No Longer Profit From Rebates But Plans Benefit; Should Sponsors Push More For Reform?

 
• By Cathy Kelly

Employers and other health plan sponsors may need to push for better targeted reforms that lower cost sharing for patients.

340B Not Designed To Pass Savings Directly To Patients, Hospitals Tell Senate Committee

 
• By Cathy Kelly

Respondents to a Senate investigation that could re-energize 340B reform efforts said hospitals offer patient assistance programs and use 340B revenue for “capital improvement projects” and “community benefit programs,” though they do not account for specific program revenue allocations.

If CMS Takes Over 340B, Will Government Allow Rebate Model Changes?

 
• By Cathy Kelly

Manufacturers have supported the proposed shift in oversight authority, which could create a more pharma-friendly environment in the drug discount program, but uncertainty remains.

More from Market Access